Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Merck Sharp & Dohme LLC
Jonathan D Spicer; Marina C Garassino; Heather Wakelee; Moishe Liberman; Terufumi Kato; Masahiro Tsuboi; Se-Hoon Lee; Ke-Neng Chen; Christophe Dooms; Margarita Majem; Ekkehard Eigendorff; Gastón L Martinengo; Olivier Bylicki; Delvys Rodríguez-Abreu; Jamie E Chaft; Silvia Novello; Jing Yang; Ashwini Arunachalam; Steven M Keller; Ayman Samkari; Shugeng Gao; KEYNOTE-671 Investigators
Biostatistics and Research Decision Sciences, Merck & Co, Rahway, NJ, USA.